AMPH Q2 2023 Earnings — Amphastar Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

AMPHAmphastar Pharmaceuticals, Inc.

$894M

Q2 2023 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$146M+18.0% YoY

Gross Profit

$73M49.9% margin

Operating Income

$37M25.3% margin

Net Income

$26M17.9% margin

EPS (Diluted)

$0.49

QoQ Revenue Growth

+4.1%

Cash Flow

Operating Cash Flow

$55M

Free Cash Flow

$46M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$1.4B

Total Liabilities

$789M

Stockholders' Equity

$589M

Cash & Equivalents

$151M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$146M	$123M	+18.0%
Gross Profit	$73M	$63M	+14.8%
Operating Income	$37M	$25M	+48.6%
Net Income	$26M	$17M	+50.6%

Revenue Segments

Research and development services

$1M100%

Geographic Segments

UNITED STATES

$144M99%

CHINA

$1M1%

FRANCE

$635,0000%